Acute panmyelosis with myelofibrosis with EVI1 amplification

Beata Grygalewicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Barbara Pieńkowska‐Grela(The Maria Sklodowska-Curie National Research Institute of Oncology), Jolanta Rygier(The Maria Sklodowska-Curie National Research Institute of Oncology), Elżbieta Patkowska(Institute for Transfusion Medicine), Renata Woroniecka, Katarzyna Borg, Anna Pastwińska(The Maria Sklodowska-Curie National Research Institute of Oncology), Paulina Krawczyk(The Maria Sklodowska-Curie National Research Institute of Oncology), Hanna Makuch‐Łasica
Cancer Genetics
May 1, 2012
10.1016/j.cancergen.2012.02.003
Cited by 4

Related Papers

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|390
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy
|Blood|2022|129
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma
|Blood|2018|112
SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism
|Cell Death and Disease|2020|41
Targeting the thioredoxin system as a novel strategy against B‐cell acute lymphoblastic leukemia
|Molecular Oncology|2019|37